Phase 0 clinical studies in oncology

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 2, 2009, Pages 204-207

  Collins, J M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; ESTROGEN; FLUORINE 18; TAMOXIFEN;

BREAST CANCER; CANCER RESEARCH; CLINICAL TRIAL; DECISION MAKING; DOSE CALCULATION; DRUG EFFICACY; ENZYME INHIBITION; FIRST IN HUMAN STUDY; HEALTH CARE POLICY; HISTORY OF MEDICINE; HUMAN; IMAGE ANALYSIS; MEDICAL ETHICS; MOLECULAR THERAPY; NON INVASIVE PROCEDURE; PHASE 0 CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECEPTOR OCCUPANCY; SHORT SURVEY; TOXICITY TESTING;

CLINICAL TRIALS AS TOPIC; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS;

EID: 58449097451     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.246     Document Type: Short Survey

References (12)

1. Murgo, A.J. et al. Designing phase 0 cancer clinical trials. Clin. Cancer Res. 14, 3675-3682 (2008).
2. Kummar, S. et al. Compressing drug development timelines in oncology using phase "0" trials. Nat. Rev. Cancer 7, 131-139 (2007).
3. Collins, J.M., Grieshaber, C.K. & Chabner, B.A. Pharmacologically guided phase I clinical trials based upon preclinical drug development. J. Natl. Cancer Inst. 82, 1321-1326 (1990).
4. Kummar, S. et al. Inhibition of poly (ADP-ribose) polymerase (PARP) by ABT-888 in patients with advanced malignancies: results of a phase 0 trial. J. Clin. Oncol. (in press).
5. Dehdashti, F., Flanagan, F.L., Mortimer, J.E., Katzenellenbogen, J.A., Welch, M.J. & Siegel, B.A. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur. J. Nucl. Med. 26, 51-56 (1999).
6. Linden, H.M. et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J. Clin. Oncol. 24, 2793-2799 (2006).
7. Frank, R. & Hargreaves, R. Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. 2, 566-580 (2003).
8. Jacobson-Kram, D. & Mills, G. Leveraging exploratory investigational new drug studies to accelerate drug development. Clin. Cancer Res. 14, 3670-3674 (2008).
9. Kinders, R. et al. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. Mol. Interv. 7, 325-334 (2007).
10. Gutierrez, M. & Collyar, D. Patient perspectives on phase 0 clinical trials. Clin. Cancer Res. 14, 3689-3691 (2008).
11. Eliopoulos, H., Giranda, V., Carr, R., Tiehen, R., Leahy, T. & Gordon, G. Phase 0 trials: an industry perspective. Clin. Cancer Res. 14, 3683-3688 (2008).
12. Robinson, W.T. Innovative early development regulatory approaches: expIND, expCTA, microdosing. Clin. Pharmacol. Ther. 83, 358-360 (2008).